Fig. 2.11 Recent acyclic tripeptide inhibitors.
shows moderate replicon potency (EC50 = 400 nM), good oral bioavaila-bility and excellent liver exposure . The replicon system was also used to obtain resistance mutations for this compound. The amino acid substitutions A156S  or A156T  significantly weaken binding. Interestingly, A156S does not significantly affect the binding of the tripeptide BILN
Was this article helpful?